Study: Alexis 2025, Dermatology and Therapy
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials
Citation
Alexis AF, Kircik L, Chovatiya R et al (2025). Dermatology and Therapy. PubMed id 40696240.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Eczema on dark skin (atopic eczema, including babies) Tier B thin
B Adults and children with atopic dermatitis in two US trials; about a quarter to a third Black or African American, over half Fitzpatrick IV-VI (n=813)
Two 8-week randomised, vehicle-controlled phase 3 trials of tapinarof cream, analysis by race and skin type.
In both trials more people on tapinarof than on vehicle reached clear or almost clear skin, in every race group. Black or African American: 43.1-47.0% on tapinarof against 17.5-24.1% on vehicle. White: 49.4-52.1% against 12.2-14.5%.
As recorded in this card: Alexis AF, Kircik L, Chovatiya R et al (2025), Dermatology and Therapy, [primary]
Note: Industry trial (several authors work for the manufacturer, Dermavant). Eight weeks only. A prescription cream, not the moisturising advice above.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.